Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (30175)	1/12/2000 10:02:00 PM
From: Torben Noerup Nielsen	Respond to of 32384

Skeeter, As long as the revaluation is done in a controlled fashion we'll be fine. Unfortunately, it's not just the nets that need to be taken down a bit. There are quite a few industries that have been high growth for some time and now they are all of a sudden mature. That means an adjustment of all their multiples. Hey, some day Ligand may go that way too. I do not for a minute think that most of our favorite biotechs will survive for another 10-20 years as independent entities. There'll be a gradual process of elimination of the ones that can't produce and absorbtion of the ones that can into the general pharmaceutical industry. In other words, buyouts and mergers. I just don't see the number of mature pharmaceutical companies growing significantly. It's the Borg philosophy :-) Cheers, Torben